Impact of Duodenal Pathology on Oral Drug Bioavailability and Disease Outcomes in Pediatric Crohn's Disease.

Discussion Despite receiving statistically significantly higher AZA doses for the treatment of Crohn’s disease (median difference 0.3 mg/kg/day; p < 0.01), children with duodenal pathology were almost twice as likely to have sub-therapeutic 6-TGN levels during the first year of treatment, compared to children without duodenal disease (RR 1.85), although this trend did not reach statistical significance.

also in 111,027 other papers